Literature DB >> 8431975

1-dehydro-melengestrol acetate inhibits the growth and protein kinase C activity of androgen-independent Dunning rat prostatic tumors.

M J Battistone1, G M Padilla, V Petrow.   

Abstract

Androgen-independent Dunning R3327-AT3 rat prostate tumors are considered an appropriate model of advanced prostate cancer in humans. We recently reported that the progestational steroid melengestrol acetate (MGA) inhibited growth of these tumors on oral administration but also induced a marked involution of adrenals and androgen target organs (prostate, seminal vesicles, and testes). We report herein that the 1-dehydro derivative of melengestrol acetate (dMGA) fed to rats for 21 days also inhibited the growth of Dunning AT3 tumors by approximately 55% without causing a significant regression of adrenals or androgen-dependent tissues. Thus, tumor-growth inhibition was induced by dMGA in the absence of glucocorticoid activity. Cytosolic AT3 tumor fractions obtained by diethylaminoethyl (DEAE)-Sephacel batch chromatography were assayed for lipid- and Ca(2+)-dependent (PKC) and -independent protein kinase activities. Prostatic cytosols had equivalent activity levels of both types of kinases (approximately 2 nmol gamma-[32P]-adenosine 5'-triphosphate (ATP) incorporated mg protein-1 min-1. The PKC activity recovered from the cytosol of untreated AT3 tumors was approximately 4 times higher. Oral administration of dMGA reduced this activity by > 95%. The relationship between protein-kinase activity levels and dMGA-induced growth inhibition of androgen-independent tumors in this animal model is discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8431975     DOI: 10.1007/bf00686156

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  24 in total

1.  PROSTATE CANCER IN THE RAT.

Authors:  W F DUNNING
Journal:  Natl Cancer Inst Monogr       Date:  1963-10

2.  Melengestrol acetate and megestrol acetate are prostatic tumor inhibiting agents.

Authors:  G M Padilla; R C Yacullo; J J Padilla; B Payne; V Petrow
Journal:  Biochem Cell Biol       Date:  1990-10       Impact factor: 3.626

3.  Expression and localization of androgen receptor in the R-3327 Dunning rat prostatic adenocarcinoma.

Authors:  V E Quarmby; W C Beckman; D B Cooke; D B Lubahn; D R Joseph; E M Wilson; F S French
Journal:  Cancer Res       Date:  1990-02-01       Impact factor: 12.701

4.  Protein kinase C subspecies in estrogen receptor-positive and -negative human breast cancer cell lines.

Authors:  E Bignon; K Ogita; A Kishimoto; Y Nishizuka
Journal:  Biochem Biophys Res Commun       Date:  1990-09-28       Impact factor: 3.575

5.  Multiple mechanisms of protein kinase C inhibition by triphenylacrylonitrile antiestrogens.

Authors:  E Bignon; M Pons; J Gilbert; Y Nishizuka
Journal:  FEBS Lett       Date:  1990-10-01       Impact factor: 4.124

6.  Application of phorbol ester to mouse skin causes a rapid and sustained loss of protein kinase C.

Authors:  A Fournier; A W Murray
Journal:  Nature       Date:  1987 Dec 24-31       Impact factor: 49.962

Review 7.  Studies and perspectives of protein kinase C.

Authors:  Y Nishizuka
Journal:  Science       Date:  1986-07-18       Impact factor: 47.728

8.  Megestrol acetate in relapsed carcinoma of prostate.

Authors:  F Daniel; P M MacLeod; C J Tyrrell
Journal:  Br J Urol       Date:  1990-03

9.  Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue.

Authors:  C O'Brian; V G Vogel; S E Singletary; N E Ward
Journal:  Cancer Res       Date:  1989-06-15       Impact factor: 12.701

10.  Treatment of R-3327 prostate tumors with a somatostatin analogue (somatuline) as adjuvant therapy following surgical castration.

Authors:  A E Bogden; J E Taylor; J P Moreau; D H Coy
Journal:  Cancer Res       Date:  1990-05-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.